References
- Lang P G. Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1979; 1: 479–92
- Zuidema J, Hilbers-Modderman E SM, Markus F WHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986; 11: 299–325
- Fleming C M, Branch R A, Wilkinson G R., et al. Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. Mol Pharmacol 1992; 41: 975–80
- Coleman M D. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993; 129: 507–13
- Zone J J. Dermatitis herpetiformis. Curr Probl Dermatol 1991; 3: 4–42
- Katz S I, Gallin I I, Slertz K C., et al. Erythema elevatum diutinum: skin and systemic manifestations, immuno-logic studies, and successful treatment with dapsone. Medicine (Baltimore) 1977; 56: 443–5
- Venning V A, Millard P R, Wojnarowska F. Dapsone as first line treatment for bullous pemphigoid. Br J Dermatol 1989; 120: 83–92
- Rogers R S, Seehafer J R, Perry H O. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 1982; 6: 215–23
- Sire D J, Johnson B L. Benign familial chronic pemphigus treated with dapsone. Arch Dermatol 1971; 103: 262–5
- Pearson R W, O'Donoghue M, Kaplan S J. Pemphigus vegetans. Its relationship to eosinophilic spongiosis and favourable response to dapsone. Arch Dermatol 1980; 116: 65–8
- Basset N, Guillot B, Michel B, et al. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol 1987; 123: 783–5
- Steffen C. Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy. Arch Dermatol 1985; 121: 921–3
- Hall R P, Lawley T J, Smith H R., et al. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med 1982; 97: 165–70
- Coburn P R, Shuster S. Dapsone and discoid lupus erythematosus. Br) Dermatol 1982; 106: 105–6
- McCormack L S, Elgart M L, Turner M LC. Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 1984; 11: 397–401
- Steiner A, Pehamberger H, Wolff K. Sulfone treatment of granuloma annulare. J Am Acad Dermatol 1985; 13: 1004–8
- Stendahl O, Molin L, Dahlgren C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone: possible mechanism in the treatment of dermatitis herpetiformis. J Clin Invest 1987; 62: 214–20
- Booth S A, Moody C E, Dahl M V., et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992; 98: 135–40
- Grossman S J, Jollow D J. Role of dapsone hydroxylamine in dapsone-induced haemolytic anaemia. J Pharmacol Exp Ther 1988; 244: 18–25
- DeGowin R L, Eppes R B, Powell R D., et al. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull WHO 1966; 35: 165–79
- Rhodes L E, Coleman M D, Lewis-Jones M S. Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus. Clin Exp Dermatol 1995; 20: 155–6
- Kelly J W, Scott J, Sandland M, et al. Vitamin E and dapsone-induced haemolysis. Arch Dermatol 1984; 120: 1582–4
- Prussick R, Ali MAM, Rosenthal D, et al. The protective effect of vitamin E on the haemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol 1992; 128: 210–13
- Rhodes L E, Tingle M D, Chu P, et al. Cimetidine improves the therapeutic/toxic ratio in patients on chronic dapsone therapy. Br] Dermatol 1995; 132: 257–62